Business Context and Reporting Period
This Form 8-K filing by Perrigo Company Plc (Perrigo) is dated December 18, 2013. The report details corporate governance changes effective upon the consummation of the Transaction Agreement dated July 28, 2013, involving Perrigo Company, Elan Corporation, plc, Leopard Company, Habsont Limited, and Perrigo Company Plc. The filing primarily addresses the appointment of new directors and officers and the resignation of former board members following the transaction.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes Versus Prior Period
The filing reports significant changes to the Company's Board of Directors and executive leadership structure effective December 18, 2013:
- Board Appointments: Eleven directors were appointed to the new Board, including Laurie Brlas, Gary M. Cohen, Jacqualyn A. Fouse, David T. Gibbons, Ran Gottfried, Ellen R. Hoffing, Michael J. Jandernoa, Gary K. Kunkle, Jr., Herman Morris, Jr., Joseph C. Papa, and Ben-Zion Zilberfarb.
- Board Resignations: Judy Brown, Lorraine Egan, John Hendrickson, and Todd Kingma resigned from the Board. The filing states these resignations were not due to any disagreement with the Company.
- Leadership Roles: Joseph C. Papa was named Chairman of the Board and President and Chief Executive Officer. Gary K. Kunkle, Jr. was named Lead Independent Director.
- Committee Assignments: The Board established an Audit Committee (chaired by Ms. Brlas), a Remuneration Committee (chaired by Ms. Hoffing), and a Nominating & Governance Committee (chaired by Mr. Cohen).
- Officer Appointments: Several individuals were appointed to executive officer roles, including Judy L. Brown (EVP and CFO), Thomas Farrington (SVP and CIO), John T. Hendrickson (EVP, Global Operations), Scott Jamison (EVP, Nutritionals), Todd W. Kingma (EVP, General Counsel), Sharon Kochan (EVP, International), Jeff Needham (EVP, Consumer Healthcare), Jatin Shah (SVP, Chief Scientific Officer), Mike Stewart (SVP, Global HR), Louis Yu (SVP, Global Quality), and Douglas Boothe (EVP, Perrigo Pharmaceuticals).
Guidance, Outlook, Risks, and Unusual Items
Compensation and Plans: New Perrigo assumed sponsorship of the 2003, 2008, and 2013 Long-Term Incentive Plans, including outstanding awards and remaining shares, subject to adjustments per the Transaction Agreement. Specific compensation details are referenced in the joint proxy statement/prospectus filed on October 15, 2013.
Risks and Uncertainties: The filing includes a forward-looking statements disclaimer highlighting several risks that could cause actual results to differ from expectations:
- Successful integration of the Elan Corporation, plc acquisition and realization of synergies.
- Timing and outcomes of pending or future litigation and government investigations.
- Patent infringement litigation and potential settlements.
- Competitive products, pricing, and foreign currency exchange rate fluctuations.
- Dependence on a small number of products for material revenue.
- Regulatory approvals, product launches, and manufacturing difficulties.
- Changes in laws affecting pricing and reimbursement (e.g., Medicare, Medicaid).
Investor Verification Checklist
- Verify the full composition of the new 11-member Board of Directors and their specific committee assignments.
- Review the joint proxy statement/prospectus filed on October 15, 2013, for detailed compensation arrangements for the new directors and executive officers.
- Confirm the status of the integration of Elan Corporation, plc, as referenced in the risk factors.
- Check the status of any pending litigation or government investigations mentioned in the forward-looking statements.
- Review the terms of the 2013 Long-Term Incentive Plan (Exhibit 10.1) regarding adjustments to awards.